Key to insitro’s approach to rethinking drug development is the use of cutting edge machine learning to model the space of cell states in health and disease. To enable that, we produce high-quality, high throughput, genomic data of iPSC-derived cellular disease models under genetic and chemical perturbation. We integrate this data with patient genotypes and clinical and molecular phenotypes to identify molecular targets for impactful therapeutics.
As a Genomic Data Scientist, you will develop and apply cutting edge methods to analyze multi-dimensional, multi-modality genomic data to uncover new disease biology. You will work with high quality functional genomic data, such as single-cell RNA-seq, of cells from diverse genetic backgrounds under multiple genetic and chemical perturbations. You will work closely with a cross-functional team of life scientists, bioengineers and machine learning scientists to design and analyze in-house experiments. You will integrate genomic data with other data modalities, such as microscopy and genetics, to investigate iPSC-derived cellular models of various diseases. Finally, you will analyze data from human cohorts and combine it with our in-house results to identify therapeutic targets and develop drugs that have high efficacy and low toxicity.
You will be joining an agile and fast growing biotech startup that has long-term stability due to significant funding. You will have ample opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. We rely on human genetic cohorts, human-derived cellular disease models, and high-throughput biology and chemistry to identify coherent patient segments, actionable therapeutic targets, and new or existing chemical matter. The goal is to deliver predictive insights to improve the probability of success and reduce the number of costly dead ends along the R&D journey. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS and is building a pipeline of wholly owned and partnered medicines leveraging its unique insights on patient biomarkers, targets, and molecules. insitro is located in South San Francisco, CA and has raised over $600M from top tech, biotech, and crossover investors since formation in 2018. For more information on insitro, please visit the company’s website at www.insitro.com.
Your application was submitted successfully.